Legal
Weekly Legal Briefing — Keytruda
Week ending August 26, 2026
1. This week’s factual summary
Monitoring covered 10 distinct questions and 70 responses: 35 brand-focused and 35 product-information responses. Responses repeatedly used “Keytruda” together with “pembrolizumab” and discussed substitution, biosimilars, dosing, administration, liver-test thresholds, drug interactions, and eligibility. The data recorded 14 biosimilar/generic tags, 23 overclaim-language tags, and 2 cross-response inconsistency flags. No compounding tags were recorded.
2. Trademark / brand-name usage patterns
Responses generally treated Keytruda as the named product and identified it as pembrolizumab. Examples include: “Keytruda is the brand name for pembrolizumab” and “Keytruda (pembrolizumab) is a biologic.”
The responses also used “Keytruda” as shorthand when discussing treatment, substitution, dosing, and administration. The data does not show responses using “Keytruda” solely as a broad term for all PD-1 drugs; comparisons separately identified Opdivo (nivolumab) and Tecentriq (atezolizumab).
3. Compounding, generic, and biosimilar language
There were 14 biosimilar/generic tags, appearing across all seven responses to each of two questions concerning pharmacy substitution and generic/biosimilar status. The responses repeatedly stated that substitution “can happen in some cases,” is “not always allowed or automatic,” and depends on prescription wording, jurisdiction, insurance/formulary rules, pharmacy availability, and approved biosimilar or interchangeability status.
Examples include: “Keytruda has no true ‘generic’ equivalent, but it may have biosimilar alternatives,” and “automatic substitution is not always allowed.” No compounding language was identified in the supplied data.
4. Language involving named competitors
The structured competitor fields recorded zero competitor mentions, but the response text named Opdivo and Tecentriq. Among the 35 brand responses, 19 also carried overclaim-language tags while discussing a named competitor. Tagged terms included “more effective,” “superior,” “stronger,” “strongest,” “best,” and “leading.”
One excerpt states that “Keytruda is more effective than Opdivo” is usually not a “simple, across-the-board conclusion.” Other responses used “best,” “stronger,” or “superior” while comparing Keytruda with Opdivo or Tecentriq.
5. Trend across weeks
Compared with August 19, responses increased from 60 to 70, while questions remained at 10. Overclaim tags rose from 15 to 23; hedging/disclaimer tags from 50 to 58; dosing tags from 15 to 17; and biosimilar/generic tags from 13 to 14. Inconsistency flags declined from 3 to 2. Structured competitor mentions remained at zero.
6. Flagged for attorney review
- 19 brand responses combined named-competitor discussion with overclaim-language tags.
- 14 responses discussed generic or biosimilar substitution.
- “Keytruda is more effective than Opdivo” and related terms appeared in comparative responses.
- Two questions produced inconsistent answer coverage: hypersensitivity language appeared in 2 of 7 administration responses, and infection-risk language in 4 of 7 eligibility responses.